Project Grant R41DA061874
Award Date
1/15/25
Completion Date
12/31/25
Dollars Obligated
$405K
Federal Agency
National Institute on Drug Abuse
Awardee
Rafias LLC (K2VXLZRME3H8)
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This $810,668 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on evaluating an immunotherapeutic compound called DRHQ as a potential treatment for stimulant use disorder, specifically methamphetamine addiction. The primary objective is to demonstrate the feasibility of DRHQ, which is moving from the lead optimization stage into preclinical development. The research will be conducted by Virogenomics...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $295,325 to Epivario Inc. to develop a novel small molecule inhibitor of the metabolic enzyme ACSS2 as a potential treatment for cocaine use disorder (CUD). The key objectives are to assess the pharmacological properties, including selectivity, efficacy on epigenetic regulation, and pharmacokinetics, of Epivario's lead ACSS2 inhibitor...
This $319,547 project grant awarded on September 15, 2023 by the National Institute on Drug Abuse (NIDA) under the Drug Abuse and Addiction Research Programs (CFDA 93.279) supports Afasci, Inc.'s research and development of a novel treatment for cocaine use disorder (CUD). The project will investigate the effects of Afasci's investigational new drug AFA-281, which inhibits both the T-type Cav3 ion channels and soluble epoxide hydrolase, on reducing cocaine-seeking behavior and hyperlocomotion in...
This $397,829 Project Grant was awarded on May 1, 2025 by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to Callentis Consulting Group LLC, a woman-owned small business. The grant supports the development of an AI-based platform to identify and validate potential drug targets and compounds for treating substance use disorders. The key products and services to be delivered include: Curated training datasets and machine learning...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $251,250 to the University of Massachusetts Medical School (UMass Medical) to conduct exploratory research on the role of the neuropeptide nociceptin (N/OFQ) in suppressing cocaine reward in the mesolimbic brain region. The funded project aims to characterize the mechanisms and circuitry by which N/OFQ signaling in the nucleus accumbens can...
This federal Project Grant award, valued at $263,119 and funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on developing NLRP3 inhibitors to address HIV-associated neuroinflammation in individuals with cocaine use. The key objectives of this grant are to: 1) computationally design and synthesize analogues of a lead compound, AMS-17, to improve its biological activity and maintain low toxicity; and 2) screen the...
This $189,644 Project Grant award from the National Institute on Drug Abuse (NIDA), funded under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to characterize and functionally validate several transcript variants of the dopamine D3 receptor (DRD3) gene in the context of cocaine addiction. The project aims to: 1) Characterize the functions of DRD3 transcript variants using heterologous expression systems; and 2) Develop and validate neuron type-specific...
This Project Grant award from the National Institute on Drug Abuse (NIDA), funded under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to investigate the "need-state hypothesis" in cocaine addiction. The $685,856 award to Pennsylvania State University, specifically the Penn State Milton S. Hershey Medical Center, aims to use an animal model to identify early indicators of addiction vulnerability and test whether a glucagon-like peptide-1 (GLP-1)...
This Project Grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to identify therapeutic molecules that can bind to the GPR26 receptor and potentially treat opioid use disorders without directly targeting opioid receptors. The $399,884 Phase I SBIR project will utilize DNA-encoded library (DEL) technology to screen 125 million compounds and identify 100 preferred hits. The awardee, Jillion Therapeutics Inc., will...
This $445,500 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research at the University of Alabama at Birmingham (UAB) to characterize the effects of chronic cocaine exposure on the nervous system of the nematode Caenorhabditis elegans. The researchers will generate comprehensive molecular, behavioral, and neuronal activity atlases in response to acute versus chronic cocaine exposure in C....